Compare Novo Nordisk A/S (NVO) vs Vanguard Dividend Appreciation Index Fund ETF (VIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? Novo Nordisk A/S trades at $38.43 (market cap $165.31B), while Vanguard Dividend Appreciation Index Fund ETF trades at $238.83 (market cap $132.40B). The key difference: Novo Nordisk A/S is the larger of the two by market cap, and Novo Nordisk A/S pays a 4.71% dividend while Vanguard Dividend Appreciation Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Vanguard Dividend Appreciation Index Fund ETF for 133 Days on average.
| NVO | VIG | |
|---|---|---|
Market Cap | $165.31B | $132.40B |
Volume | 11,432,838 | 1,287,188 |
Sector | Health | — |
52-Week High | $63.98 | $246.61 |
52-Week Low | $35.29 | $210.70 |
Typical Hold Time | 116 Days | 133 Days |
Enterprise Value | $179.56B | — |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
VIG trades at $237.99, up 0.42% with a bullish technical signal from moving averages. The ETF focuses on dividend growth companies with 10+ years of consecutive dividend increases, offering a lower yield but stronger growth profile compared to peers. Recent news highlights its 7.5% quarterly dividend increase and long-term return potential averaging 10% annually since inception.
Outlook remains positive for investors seeking dividend growth with moderate risk, though the low current yield and exclusion of high-yield stocks present trade-offs. Key risks include market volatility and the ETF's specific eligibility rules limiting certain holdings. The growth-oriented strategy appeals to long-term investors prioritizing increasing income over current yield.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Vanguard Dividend Appreciation Index Fund ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →
